RU2017106100A3 - - Google Patents

Download PDF

Info

Publication number
RU2017106100A3
RU2017106100A3 RU2017106100A RU2017106100A RU2017106100A3 RU 2017106100 A3 RU2017106100 A3 RU 2017106100A3 RU 2017106100 A RU2017106100 A RU 2017106100A RU 2017106100 A RU2017106100 A RU 2017106100A RU 2017106100 A3 RU2017106100 A3 RU 2017106100A3
Authority
RU
Russia
Application number
RU2017106100A
Other versions
RU2696135C2 (ru
RU2017106100A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017106100A publication Critical patent/RU2017106100A/ru
Publication of RU2017106100A3 publication Critical patent/RU2017106100A3/ru
Application granted granted Critical
Publication of RU2696135C2 publication Critical patent/RU2696135C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017106100A 2014-08-01 2015-07-30 6,7-ДИГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИН-4(5Н)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 RU2696135C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179602.9 2014-08-01
EP14179602 2014-08-01
PCT/EP2015/067538 WO2016016383A1 (en) 2014-08-01 2015-07-30 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

Publications (3)

Publication Number Publication Date
RU2017106100A RU2017106100A (ru) 2018-09-03
RU2017106100A3 true RU2017106100A3 (ru) 2019-02-21
RU2696135C2 RU2696135C2 (ru) 2019-07-31

Family

ID=51257441

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017106100A RU2696135C2 (ru) 2014-08-01 2015-07-30 6,7-ДИГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИН-4(5Н)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2

Country Status (9)

Country Link
US (1) US10017514B2 (ru)
EP (1) EP3174884B1 (ru)
JP (1) JP6661605B2 (ru)
CN (1) CN107001373B (ru)
AU (1) AU2015295301B2 (ru)
CA (1) CA2954222C (ru)
ES (1) ES2702194T3 (ru)
RU (1) RU2696135C2 (ru)
WO (1) WO2016016383A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
US10967078B2 (en) 2014-12-03 2021-04-06 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
CA2967153A1 (en) 2014-12-03 2016-06-09 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-.alpha.]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
AU2016374568B2 (en) 2015-12-18 2020-08-27 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
RS60981B1 (sr) 2015-12-18 2020-11-30 Janssen Pharmaceutica Nv Radiooznačeni mglur2/3 pet ligandi
US9849817B2 (en) 2016-03-16 2017-12-26 Ford Global Technologies, Llc Composite seat structure
WO2019054411A1 (ja) 2017-09-13 2019-03-21 日本電気株式会社 リチウムイオン二次電池
KR20200090843A (ko) * 2017-11-24 2020-07-29 다이닛본 스미토모 세이야꾸 가부시끼가이샤 6, 7-디히드로 피라졸로[1, 5-a]피라지논 유도체 및 그 의약 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004054665A1 (de) * 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
KR101753826B1 (ko) * 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,2,4―트리아졸로[4,3―a]피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
JP2013545822A (ja) * 2010-12-17 2013-12-26 ヴァンダービルト ユニバーシティー mGluR5受容体のアロステリック調節剤としての、二環式トリアゾールラクタムおよびピラゾールラクタム
CA2853923A1 (en) 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
US20130345204A1 (en) * 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
US20130345205A1 (en) * 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
JP2015520239A (ja) * 2012-06-20 2015-07-16 ヴァンダービルト ユニバーシティー Mglur5受容体のアロステリック調節剤としての置換二環式アルコキシピラゾール類似体
WO2014064028A1 (en) 2012-10-23 2014-05-01 F. Hoffmann-La Roche Ag Mglu2/3 antagonists for the treatment of autistic disorders
AU2015295300B2 (en) * 2014-08-01 2019-05-02 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mGluR2 receptors

Also Published As

Publication number Publication date
EP3174884A1 (en) 2017-06-07
AU2015295301A1 (en) 2017-01-19
CN107001373B (zh) 2020-01-07
RU2696135C2 (ru) 2019-07-31
US10017514B2 (en) 2018-07-10
ES2702194T3 (es) 2019-02-27
CN107001373A (zh) 2017-08-01
WO2016016383A1 (en) 2016-02-04
CA2954222C (en) 2022-11-29
US20170267682A1 (en) 2017-09-21
JP2017523202A (ja) 2017-08-17
EP3174884B1 (en) 2018-09-26
RU2017106100A (ru) 2018-09-03
CA2954222A1 (en) 2016-02-04
AU2015295301B2 (en) 2019-05-09
JP6661605B2 (ja) 2020-03-11

Similar Documents

Publication Publication Date Title
BR112016023162A2 (ru)
BR112016022984A2 (ru)
BR112016018895A2 (ru)
BR112016019075A2 (ru)
BR112016027588A2 (ru)
BR112016027265A2 (ru)
BR112016018868A2 (ru)
BR112016022779A2 (ru)
BR112016022045A2 (ru)
BR112016017972A2 (ru)
BR112016021718A2 (ru)
BR112016018369A2 (ru)
BR112016016008A2 (ru)
BR112016008129A2 (ru)
BR112016016298A2 (ru)
BR112016030584A2 (ru)
BR112016026822A2 (ru)
BR112016015666A2 (ru)
BR112016026638A2 (ru)
BR112016025577A2 (ru)
BR112016020335A2 (ru)
BR112016022559A2 (ru)
RU2017106100A3 (ru)
BR112016027445A2 (ru)
RU2017107468A3 (ru)